TLDR Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50 Stock has surged 47-48.7% in the past yearTLDR Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50 Stock has surged 47-48.7% in the past year

Johnson & Johnson (JNJ) Stock: What to Expect From Earnings Wednesday

TLDR

  • Johnson & Johnson reports Q4 fiscal 2025 earnings before market open on January 21 with EPS expected at $2.49-$2.50
  • Stock has surged 47-48.7% in the past year, crushing the S&P 500’s 14.7% return over the same period
  • Stelara faces mounting pressure from multiple biosimilar competitors launched in 2025, expected to weigh heavily on Q4 results
  • Company announced $55 billion U.S. investment plan including a $2 billion North Carolina biologics facility creating 5,000 jobs
  • Maryland jury awarded $1.56 billion in talc lawsuit, the largest single-plaintiff verdict against JNJ, which plans to appeal

Johnson & Johnson releases fourth-quarter fiscal 2025 results on Wednesday, January 21, before the market opens. Analysts project earnings per share will climb 22% to around $2.49-$2.50, while revenue should grow 7.3% year-over-year to approximately $24.14 billion.


JNJ Stock Card
Johnson & Johnson, JNJ

The stock has been on fire. JNJ shares rocketed 47-48.7% over the past 12 months, obliterating the S&P 500’s 14.7% advance.

Wall Street analysts show mixed feelings heading into the report. Seven rate the stock a Buy while five recommend Hold, according to TipRanks. The average price target of $221.09 implies only 1.1% upside from current levels.

The Dividend King maintains its impressive payout streak. JNJ has increased dividends for over 60 consecutive years and currently pays $1.30 per share quarterly, yielding 2.50%.

Key Drugs Drive Innovative Medicine Growth

The Innovative Medicine segment should power Q4 results. Darzalex, Tremfya, and Erleada are expected to post strong numbers. Analysts forecast Darzalex sales at $3.74 billion, Tremfya at $1.36 billion, and Erleada at $936 million.

Newer launches are picking up steam. Carvykti, Tecvayli, Talvey, Rybrevant, Caplyta, Lazcluze, and Spravato should all contribute to growth.

But Stelara is getting crushed. Multiple biosimilar versions hit the U.S. market in 2025 from Amgen, Teva, Samsung Bioepis/Sandoz, and others. The loss of exclusivity hammered the Innovative Medicines segment by 1,070 basis points in Q3. Analysts expect the damage to accelerate in Q4 as more biosimilars enter the market. Stelara sales are pegged at just $1.36 billion.

Imbruvica faces its own challenges from oral competitors and Medicare Part D redesign impacts. Estimates stand at $670 million. Generic competition for Zytiga and Remicade continues nibbling away at sales.

The MedTech business has bounced back in recent quarters. Cardiovascular acquisitions Abiomed and Shockwave are performing well. Surgery, Vision, and electrophysiology products are gaining traction. Consensus estimates peg MedTech revenue at $8.71 billion.

China remains problematic. The government’s volume-based procurement program keeps squeezing MedTech margins through forced price cuts.

JNJ dropped positive Caplyta data on January 16. Phase 3 trials showed the drug boosted remission rates in major depressive disorder when combined with antidepressants. After six months, 65% of patients achieved remission. The FDA approved Caplyta for this use in November 2025.

The company cut a deal with the Trump administration on drug pricing while securing tariff exemptions. It’s also moving forward with major U.S. manufacturing expansion plans totaling $55 billion. A $2 billion biologics plant in Wilson, North Carolina will create roughly 5,000 jobs.

The talc litigation headache persists. A Maryland jury hit JNJ with a $1.56 billion verdict, the biggest single-plaintiff award yet, over alleged mesothelioma from baby powder. The company insists the product never contained asbestos and will appeal the decision.

2026 Guidance in Focus

Management previously signaled consensus estimates for 2026 were too conservative. Back in October, JNJ expected revenue growth above 5% versus analyst forecasts of 4.6%. Earnings per share were projected roughly 5 cents higher than the October consensus of $11.39.

The stock trades at 19.01 times forward earnings, above the industry average of 17.73 and JNJ’s five-year mean of 15.65. The company has topped earnings expectations in each of the last four quarters with an average beat of 3.75%.

Investors will scrutinize updated 2026 guidance and management commentary on biosimilar competition, talc litigation, and pipeline progress when JNJ reports January 21.

The post Johnson & Johnson (JNJ) Stock: What to Expect From Earnings Wednesday appeared first on Blockonomi.

Market Opportunity
PoP Planet Logo
PoP Planet Price(P)
$0.01328
$0.01328$0.01328
+0.22%
USD
PoP Planet (P) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Will XRP Price Increase In September 2025?

Will XRP Price Increase In September 2025?

Ripple XRP is a cryptocurrency that primarily focuses on building a decentralised payments network to facilitate low-cost and cross-border transactions. It’s a native digital currency of the Ripple network, which works as a blockchain called the XRP Ledger (XRPL). It utilised a shared, distributed ledger to track account balances and transactions. What Do XRP Charts Reveal? […]
Share
Tronweekly2025/09/18 00:00
Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

The post Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be appeared on BitcoinEthereumNews.com. Jordan Love and the Green Bay Packers are off to a 2-0 start. Getty Images The Green Bay Packers are, once again, one of the NFL’s better teams. The Cleveland Browns are, once again, one of the league’s doormats. It’s why unbeaten Green Bay (2-0) is a 8-point favorite at winless Cleveland (0-2) Sunday according to betmgm.com. The money line is also Green Bay -500. Most expect this to be a Packers’ rout, and it very well could be. But Green Bay knows taking anyone in this league for granted can prove costly. “I think if you look at their roster, the paper, who they have on that team, what they can do, they got a lot of talent and things can turn around quickly for them,” Packers safety Xavier McKinney said. “We just got to kind of keep that in mind and know we not just walking into something and they just going to lay down. That’s not what they going to do.” The Browns certainly haven’t laid down on defense. Far from. Cleveland is allowing an NFL-best 191.5 yards per game. The Browns gave up 141 yards to Cincinnati in Week 1, including just seven in the second half, but still lost, 17-16. Cleveland has given up an NFL-best 45.5 rushing yards per game and just 2.1 rushing yards per attempt. “The biggest thing is our defensive line is much, much improved over last year and I think we’ve got back to our personality,” defensive coordinator Jim Schwartz said recently. “When we play our best, our D-line leads us there as our engine.” The Browns rank third in the league in passing defense, allowing just 146.0 yards per game. Cleveland has also gone 30 straight games without allowing a 300-yard passer, the longest active streak in the NFL.…
Share
BitcoinEthereumNews2025/09/18 00:41
Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

The Bank of Canada lowered its overnight rate to 2.5% on Wednesday, responding to mounting economic damage from US tariffs and a slowdown in hiring. The quarter-point cut was the first since March and met predictions from markets and economists. Governor Tiff Macklem, speaking in Ottawa, said the decision was unanimous. “With a weaker economy […]
Share
Cryptopolitan2025/09/17 23:09